Devyser Diagnostics
131
SEK
-0.76 %
DVYSR
First North Stockholm
Medical Equipment & Services
Health Care
Less than 1K followers
-0.76%
-1.13%
+10.55%
-0.76%
+20.74%
+65.4%
+58.21%
-
+47.19%
Devyser Diagnostics develops, manufactures, and sells genetic tests to laboratories globally. The products are used for DNA tests in oncology, transplantation, and hereditary diseases to enable tailored cancer treatment, diagnosis of a large number of genetic diseases, and follow-up of transplant patients. The company is headquartered in Hägersten.
Read moreMarket cap
2.17B SEK
Turnover
2.47M SEK
Revenue
216.9M
EBIT %
-26.88 %
P/E
-
Dividend yield-%
-
Financial calendar
29.4
2025
Interim report Q1'25
14.5
2025
General meeting '25
22.7
2025
Interim report Q2'25
ShowingAll content types
Correction: Too low direct sales reported in year-end report "Devyser Diagnostics AB publishes year-end report for January to December 2024"

Devyser Diagnostics, Audiocast with teleconference, Q4'24
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Devyser Diagnostics AB publishes year-end report for January to December 2024
Invitation to audiocast for Devyser’s Q4 report 2024
Devyser launches a new updated NGS assay to simplify thalassemia testing
Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK
Devyser publishes preliminary result for Q4 2024
CEO Fredrik Alpsten leaves Devyser and Fredrik Dahl is appointed new acting CEO of Devyser
Devyser achieves Class D IVDR approval for its RHD product

Devyser Diagnostics, Capital Markets Day, 2024
Nomination Committee Appointed Ahead of the 2025 Annual General Meeting in Devyser Diagnostics AB
Redeye: Devyser Q3 - All eyes on Q4
